论文部分内容阅读
目的 了解2013-2017年本院分离的鲍曼不动杆菌的感染分布特征和耐药情况,为临床合理使用抗生素提供实验依据.方法 收集本院住院部2013-2017年分离的777株鲍曼不动杆菌,运用梅里埃VITEK2-Compact进行细菌鉴定和抗生素敏感试验,药敏结果按CLSI标准判定,采用SPSS 19.0软件统计5年来鲍曼不动杆菌的检出率和耐药情况.结果 2013-2017年鲍曼不动杆菌的临床标本检出率分别为1.15％(73/6 354)、1.46％(104/7 135)、1.94％(155/7 986)、2.32％(194/8 357)和2.71％(251/9 249),呈逐年上升的趋势,差异有统计学意义(χ2=63.12,P＜0.05).5年来,临床分离鲍曼不动杆菌以痰标本的检出率最高,为1.62％～3.93％,呈逐年上升趋势,差异有统计学意义(χ2=50.97,P＜0.05);临床科室以ICU(2.75％～5.66％)、神经外科(1.77％～4.35％)和呼吸内科(0.95％～2.40％)的检出率最高.临床分离鲍曼不动杆菌对临床常用抗生素耐药情况严重,其中对头孢菌素类耐药尤为明显(50.48％～96.41％),对左旋氧氟沙星的耐药率上升最严重(12.33％～40.24％),差异有统计学意义(χ2=28.23,P＜0.05),多重耐药率也呈逐年增高的趋势(30.14％～50.20％),差异有统计学意义(χ2=12.31,P＜0.05).结论 鲍曼不动杆菌的检出和耐药情况日益严重,应加强鲍曼不动杆菌的耐药监测,临床使用抗生素的监管,并制定合理的抗生素使用方案,以防止耐药菌株的播散流行.“,”Objective To investigate the clinical infection characteristics and drug resistance of Acinetobacter baumannii isolated from 2013 to 2017, and provide laboratory data for clinical use of antimicrobial agents reasonably. Methods The clinical department distribution, specimen type distribution and drug resistance of 777 strains of Acinetobacter baumannii isolated from inpatient department of our hospital from 2013 to 2017 were retrospectively analyzed. Identification of the isolates was confirmed with the VITEK-2 Compact System. The antimicrobial susceptibility were determined by using the VITEK-2 Compact System and interpreed according to the Clinical and Laboratory Standards Institute guidelines (CLSI) Statistical analysis was performed on the detection rate and drug resistance of Acinetobacter baumannii over the past 5 years using SPSS 19.0 statistical software. Results The clinical specimens of Acinetobacter baumannii in 2013-2017 were 1.15％, 1.46％, 1.94％, 2.32％. and 2.71％, respectively, showing an increasing trend year by year (χ2=63.12, P＜0.05). In the past 5 years, the clinical detection rate of Acinetobacter baumannii was the highest, ranging from 1.62％ to 3.93％. showing an increasing trend year by year (χ2=50.97, P＜0.05). The clinical department had the highest detection rate in ICU (2.75％-5.66％), neurosurgery (1.77％-4.35％) and respiratory medicine (0.95％ ～2.40％). Clinical isolates of Acinetobacter baumannii had serious resistance to clinically used antibiotics, among which cephalosporins were particularly resistant (50.48％-96.41％). The resistance rate to levofloxacin increased the most (12.33％～40.24％) (χ2=28.23, P＜0.05), and the multi-drug resistance rate also increased year by year (30.14％～50.20％) (χ2=12.31, P＜0.05). Conclusions The detection and drug resistance of Acinetobacter baumannii is becoming more and more serious. It is necessary to strengthen the drug resistance monitoring of Acinetobater baumannii, the regulation of clinical use of antibiotics, and formulate a rational antibiotic use program to prevent the spread of drug-resistant strains.